Holen Sie sich die Stockscreener-App
0.4422
2.12%
0.0092
Handel nachbörslich:
.44
-0.0022
-0.50%
Schlusskurs vom Vortag:
$0.433
Offen:
$0.43
24-Stunden-Volumen:
532.76K
Relative Volume:
1.29
Marktkapitalisierung:
$47.92M
Einnahmen:
$5.12M
Nettoeinkommen (Verlust:
$-67.00M
KGV:
-0.3008
EPS:
-1.47
Netto-Cashflow:
$-38.94M
1W Leistung:
-15.30%
1M Leistung:
-31.87%
6M Leistung:
-69.50%
1J Leistung:
-92.53%
1-Tages-Spanne:
$0.3861
$0.4481
1-Wochen-Bereich:
$0.3861
$0.548
52-Wochen-Spanne:
$0.3861
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Firmenname
Verrica Pharmaceuticals Inc
Sektor
Branche
Telefon
484-453-3300
Adresse
10 NORTH HIGH STREET, WEST CHESTER, PA
Vergleichen Sie VRCA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
0.4422 | 47.92M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Hochstufung | Needham | Hold → Buy |
| 2023-03-22 | Eingeleitet | Jefferies | Buy |
| 2023-02-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-24 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-24 | Eingeleitet | Needham | Buy |
| 2019-02-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive: Verrica Pharmaceuticals CEO Fireside Chat at Major Healthcare Conference - Stock Titan
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Verrica Pharmaceuticals appoints new CMO to advance skin treatments By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer - GlobeNewswire
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
Verrica Pharmaceuticals appoints new CMO to advance skin treatments - Investing.com
Dermatology Drug Pioneer Joins Verrica to Accelerate YCANTH Growth - Stock Titan
Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News
Verrica Pharmaceuticals Reports Positive Q4 2024 Results - TipRanks
Verrica Pharmaceuticals’ chief legal officer sells shares for $2,804 By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals’ chief legal officer sells shares for $2,804 - Investing.com
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates - MSN
Equities Analysts Offer Predictions for VRCA Q4 Earnings - Defense World
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MSN
Brookline Capital Management Comments on VRCA Q1 Earnings - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Earns “Hold” Rating from Needham & Company LLC - Defense World
GLP-1 Receptor Agonist Market Projected To Witness Substantial Growth, 2025-2032: Verrica Pharmaceuticals, - EIN News
Verrica Pharmaceuticals stock hits 52-week low at $0.57 By Investing.com - Investing.com Australia
Verrica Pharmaceuticals stock hits 52-week low at $0.57 - Investing.com India
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 - Investing.com Australia
Strategic Growth and Market Positioning Drive Buy Rating for Verrica Pharmaceuticals - TipRanks
Verrica Pharma's Q4 Net Loss Narrows, Revenue Declines - Nasdaq
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... - Yahoo
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlig - GuruFocus.com
Verrica Pharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Verrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c) - TipRanks
Verrica Pharmaceuticals Inc. SEC 10-K Report - TradingView
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Holdings Raised by Rhumbline Advisers - Defense World
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MyChesCo
Common Warts Clinical and Non-Clinical Studies, Key Companies, - openPR
Verrica Pharmaceuticals Announces Q4 & Full Year 2024 Financial Results Webcast - MyChesCo
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 - The Manila Times
When Will Verrica Pharmaceuticals Release Its 2024 Financial Results? - StockTitan
Verrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care Conference - MSN
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN
Verrica Pharmaceuticals stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada
Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):